LUC00023I2 - - Google Patents

Info

Publication number
LUC00023I2
LUC00023I2 LU00023C LUC00023C LUC00023I2 LU C00023 I2 LUC00023 I2 LU C00023I2 LU 00023 C LU00023 C LU 00023C LU C00023 C LUC00023 C LU C00023C LU C00023 I2 LUC00023 I2 LU C00023I2
Authority
LU
Luxembourg
Application number
LU00023C
Original Assignee
Sk Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Chemicals Co Ltd filed Critical Sk Chemicals Co Ltd
Publication of LUC00023I1 publication Critical patent/LUC00023I1/fr
Publication of LUC00023I2 publication Critical patent/LUC00023I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
LU00023C 2003-01-28 2017-06-21 LUC00023I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/353,753 US7041635B2 (en) 2003-01-28 2003-01-28 Factor VIII polypeptide
PCT/KR2003/002277 WO2004067566A1 (fr) 2003-01-28 2003-10-27 Polypeptide de facteur viii

Publications (2)

Publication Number Publication Date
LUC00023I1 LUC00023I1 (fr) 2017-06-21
LUC00023I2 true LUC00023I2 (fr) 2017-09-08

Family

ID=32736253

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00023C LUC00023I2 (fr) 2003-01-28 2017-06-21

Country Status (14)

Country Link
US (1) US7041635B2 (fr)
EP (2) EP2253645B1 (fr)
KR (1) KR100642293B1 (fr)
CN (1) CN100404552C (fr)
AU (1) AU2003274766B8 (fr)
BE (1) BE2017C021I2 (fr)
CA (1) CA2514646C (fr)
DK (2) DK2253645T3 (fr)
ES (1) ES2446041T3 (fr)
FR (1) FR17C1024I2 (fr)
HK (1) HK1150840A1 (fr)
LU (1) LUC00023I2 (fr)
NL (1) NL300878I2 (fr)
WO (1) WO2004067566A1 (fr)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183344B2 (en) * 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
MXPA05010773A (es) 2003-04-09 2005-12-12 Neose Technologies Inc Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos.
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2005012484A2 (fr) 2003-07-25 2005-02-10 Neose Technologies, Inc. Conjugues anticorps-toxines
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
DE602004026474D1 (de) * 2003-12-03 2010-05-20 Univ Rochester Rekombinanter faktor viii mit erhöhter spezifischer aktivität
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
CN101072789B (zh) 2004-01-08 2013-05-15 生物种属学股份公司 肽的o-连接的糖基化
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
JP5948627B2 (ja) 2004-10-29 2016-07-20 レイショファーム ゲーエムベーハー 線維芽細胞成長因子（ｆｇｆ）のリモデリングと糖質ペグ化
EP1858543B1 (fr) 2005-01-10 2013-11-27 BioGeneriX AG Facteur de stimulation de colonie de granulocytes glycopegylé
EP2386571B1 (fr) 2005-04-08 2016-06-01 ratiopharm GmbH Compositions et méthodes utilisées pour la préparation de mutants par glycosylation de l'hormone de croissance humaine résistant à la protéase
JP2008537680A (ja) * 2005-04-14 2008-09-25 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 安定性の増大された改変型凝固第ｖｉｉｉ因子およびその誘導体
EP2975135A1 (fr) 2005-05-25 2016-01-20 Novo Nordisk A/S Facteur IX glycopégylé
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (fr) 2005-11-03 2007-05-18 Neose Technologies, Inc. Purification de sucre de nucleotide en utilisant des membranes
JP2009518345A (ja) 2005-12-07 2009-05-07 テフニーシェ ウニヴェルジテート ミュンヘン 因子ｖｉｉｉおよび因子ｖｉｉｉ様タンパク質に対する小型ペプチドおよびペプチド模倣物の親和性リガンド
US20090203077A1 (en) * 2006-06-30 2009-08-13 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
WO2008005847A2 (fr) * 2006-06-30 2008-01-10 The Regents Of The University Of Michigan Procédé de production de protéines de type facteur viii par des procédés recombinants
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
JP2010505874A (ja) 2006-10-03 2010-02-25 ノヴォ ノルディスク アー／エス ポリペプチドコンジュゲートの精製方法
US9441030B2 (en) 2007-02-23 2016-09-13 Sk Chemicals Co., Ltd. Process for producing and purifying factor VIII and its derivatives
KR20150064246A (ko) 2007-04-03 2015-06-10 바이오제너릭스 게엠베하 글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법
CA2690611C (fr) 2007-06-12 2015-12-08 Novo Nordisk A/S Procede ameliore pour la production de sucres de nucleotide
CN101965409A (zh) 2007-11-01 2011-02-02 罗切斯特大学 具有增加的稳定性的重组因子viii
US20100286067A1 (en) * 2008-01-08 2010-11-11 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
WO2009108806A1 (fr) 2008-02-27 2009-09-03 Novo Nordisk A/S Molécules de facteur viii conjuguées
CN104045716A (zh) * 2008-05-16 2014-09-17 拜耳医药保健有限公司 靶向性凝固因子及其使用方法
CA2748314C (fr) 2009-02-03 2018-10-02 Amunix Operating Inc. Polypeptides recombinants etendus et compositions les comprenant
WO2011028229A1 (fr) 2009-08-24 2011-03-10 Amunix Operating Inc. Compositions de facteur ix de coagulation et leurs procédés de fabrication et d'utilisation
CA2776503C (fr) 2009-10-02 2020-07-28 The Children's Hospital Of Philadelphia Compositions et procedes pour renforcer la fonction du facteur de coagulation viii
CA2782424C (fr) 2009-12-06 2021-07-27 Biogen Idec Hemophilia Inc. Polypeptides chimeriques et hybrides de facteur viii-fc, et procedes d'utilisation de ceux-ci
US20130216513A1 (en) 2010-07-09 2013-08-22 Biogen Idec Hemophilia Inc. Chimeric Clotting Factors
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
SG10201509149VA (en) * 2010-11-05 2015-12-30 Baxter Int A new variant of antihemophilic factor viii having increased specific activity
US9486507B2 (en) 2011-06-10 2016-11-08 Biogen Ma Inc. Pro-coagulant compounds and methods of use thereof
WO2013009627A2 (fr) 2011-07-08 2013-01-17 Biogen Idec Hemophilia Inc. Polypeptides chimériques et hybrides du facteur viii et leurs procédés d'utilisation
US10656167B2 (en) 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
CA2850579A1 (fr) 2011-10-18 2013-04-25 Carsten Horn Procede pour l'amelioration de la stabilite du facteur viii purifie apres la reconstitution
AU2012318303B2 (en) 2011-10-18 2015-09-03 Csl Behring Gmbh Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of Factor VIII
KR20140083036A (ko) 2011-10-18 2014-07-03 체에스엘 베링 게엠베하 인자 ｖｉｉｉ의 생체이용률을 향상시키기 위한 황산화 글리코사미노글리칸의 용도
PT2804623T (pt) 2012-01-12 2019-11-18 Bioverativ Therapeutics Inc Polipéptidos quiméricos do fator viii e suas utilizações
ES2899848T3 (es) 2012-01-12 2022-03-15 Bioverativ Therapeutics Inc Reducción de la inmunogenicidad contra el factor VIII en individuos sometidos a una terapia con factor VIII
LT3564260T (lt) 2012-02-15 2023-01-10 Bioverativ Therapeutics Inc. Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai
CA2864126A1 (fr) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Proteines de facteur viii de recombinaison
EP4079316A1 (fr) 2012-06-08 2022-10-26 Bioverativ Therapeutics Inc. Composés procoagulants
JP2015525222A (ja) 2012-06-08 2015-09-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． キメラ性凝固因子
EP3404105A1 (fr) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Lignée cellulaire exprimant des polypeptides du facteur viii à chaîne unique et ses utilisations
KR101395736B1 (ko) * 2012-07-10 2014-05-16 아주대학교산학협력단 인간 혈액응고인자 ⅷ 도메인 특이적 항체 및 이의 제조방법
BR112015000267B1 (pt) 2012-07-11 2023-01-24 Bioverativ Therapeutics Inc. Proteínas quiméricas, e composição farmacêutica
EP2877202A4 (fr) 2012-07-25 2016-06-01 Biogen Ma Inc Essai de surveillance de facteur sanguin et utilisations de celui-ci
EP2908847B1 (fr) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Procédés d'utilisation d'une dose fixe d'un facteur de coagulation
EP3943102A1 (fr) 2012-10-30 2022-01-26 Bioverativ Therapeutics Inc. Procédé d'utilisation de polypeptide du facteur viii
FI2956477T4 (fi) * 2013-02-15 2024-04-24 Bioverativ Therapeutics Inc Optimoitu tekijä viii:n geeni
UY35462A (es) 2013-03-15 2014-10-31 Biogen Idec Inc Formulación de un polipéptido del factor viii.
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
EP2796145B1 (fr) 2013-04-22 2017-11-01 CSL Ltd. Un complexe covalent de facteur von willebrand et de faktor viii conjugé par un pont disulfure
NZ713904A (en) 2013-06-28 2022-02-25 Bioverativ Therapeutics Inc Thrombin cleavable linker with xten and its uses thereof
EP3875106A1 (fr) 2013-08-08 2021-09-08 Bioverativ Therapeutics Inc. Purification des molécules fviii chimériques
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
EP3065769A4 (fr) 2013-11-08 2017-05-31 Biogen MA Inc. Composé de fusion procoagulant
WO2015085276A1 (fr) 2013-12-06 2015-06-11 Biogen Idec Ma Inc. Outils pharmacocinétiques de population et leurs utilisations
CN116621991A (zh) 2014-01-10 2023-08-22 比奥贝拉蒂治疗公司 因子viii嵌合蛋白及其用途
WO2015107222A1 (fr) * 2014-01-20 2015-07-23 Octapharma Ag Procédé de fabrication de facteur viii ayant un rapport amélioré de fviii:c/fviii:ag
EP3102589A1 (fr) 2014-02-04 2016-12-14 Biogen MA Inc. Chromatographie par échange cationique utilisée dans le mode de fixation par écoulement pour enrichir les modifications post-traductionnelles
BR112017002090B1 (pt) 2014-08-04 2021-06-01 Csl Limited Composição aquosa de fator viii de coagulação e método de estabilizar uma molécula de fviii
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
CA2978374A1 (fr) 2015-03-06 2016-09-15 Csl Behring Recombinant Facility Ag Facteur von willebrand modifie presentant une demi-vie amelioree
DK3297656T3 (da) 2015-05-22 2020-03-09 CSL Behring Lengnau AG Trunkeret von Willebrand Faktor polypeptider til behandling af hæmofili
RU2017145002A (ru) 2015-05-22 2019-06-24 Цсл Беринг Ленгнау Аг Способы получения модифицированного фактора фон виллебранда
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
WO2017050820A1 (fr) * 2015-09-22 2017-03-30 Novo Nordisk A/S Protéines de fusion du facteur viii
CN108884145B (zh) 2015-11-13 2023-08-22 武田药品工业株式会社 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
JP6695426B2 (ja) 2015-11-13 2020-05-20 バクスアルタ インコーポレイテッド 組換えｆｖｉｉｉ変異型をコードする血友病ａ遺伝子治療用高発現ウイルスベクター
JP6851381B6 (ja) 2016-01-07 2021-04-21 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 変異切断型フォンウィルブランド因子
PL3411478T3 (pl) 2016-02-01 2022-10-03 Bioverativ Therapeutics Inc. Geny zoptymalizowanego czynnika VIII
JP7235511B2 (ja) 2016-06-24 2023-03-08 モガム・インスティテュート・フォー・バイオメディカル・リサーチ 組換え型一本鎖ｆｖｉｉｉおよびその化学コンジュゲート
WO2017222337A1 (fr) 2016-06-24 2017-12-28 재단법인 목암생명과학연구소 Protéine chimère comprenant les facteurs fviii et vwf, et utilisation de celle-ci
JP6351679B2 (ja) * 2016-09-30 2018-07-04 エスケー ケミカルズ カンパニー リミテッド 第ｖｉｉｉ因子とその誘導体の製造及び精製方法
TW201828975A (zh) 2016-11-11 2018-08-16 瑞士商Ｃｓｌ貝林重組技能公司 用於治療血友病之截短型類血友病因子（ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ ｆａｃｔｏｒ）多肽類
JP2020504082A (ja) 2016-11-11 2020-02-06 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 血液凝固障害の処置又は予防における血管外投与のための切断型フォン・ヴィルブランド因子ポリペプチド
EP3548066A1 (fr) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc. Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques
MX2019006446A (es) 2016-12-02 2019-12-11 Bioverativ Therapeutics Inc Métodos para inducir tolerancia inmunológica a factores de coagulación.
WO2018234518A1 (fr) 2017-06-22 2018-12-27 CSL Behring Lengnau AG Modulation de l'immunogénicité de fviii par vwf tronqué
SG11202000764RA (en) 2017-08-09 2020-02-27 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
CA3078625C (fr) 2017-10-09 2023-01-17 Terumo Bct Biotechnologies, Llc Recipient de lyophilisation et son procede d'utilisation
US20210038744A1 (en) 2018-02-01 2021-02-11 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor viii
IL277713B2 (en) 2018-04-04 2024-09-01 Sigilon Therapeutics Inc Implantable particles and related methods
SG11202010767SA (en) 2018-05-18 2020-11-27 Bioverativ Therapeutics Inc Methods of treating hemophilia a
TW202006141A (zh) 2018-07-16 2020-02-01 美商巴克斯歐塔公司 使用編碼具有增加表現的重組fviii變異體之病毒載體的a型血友病之基因療法
BR112021002017A2 (pt) 2018-08-09 2021-05-11 Bioverativ Therapeutics Inc. moléculas de ácido nucleico e usos das mesmas para terapia genética não viral
US20220118063A1 (en) * 2018-09-19 2022-04-21 Cell Machines, Inc. Methods and compositions related to improved factor viii long half-life coagulation complexes
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
EA202191977A1 (ru) 2019-01-16 2021-12-15 Баксалта Инкорпорейтед Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии а
US11529427B2 (en) 2019-02-15 2022-12-20 Crispr Therapeutics Ag Gene editing for hemophilia A with improved factor VIII expression
WO2020185916A1 (fr) 2019-03-14 2020-09-17 Terumo Bct Biotechnologies, Llc Agencement de remplissage de contenant de lyophilisation, système et procédé d'utilisation
EP3736286A1 (fr) 2019-05-09 2020-11-11 Biotest AG Molécule de facteur viii à chaîne unique
BR112021025426A2 (pt) 2019-06-19 2022-06-21 Bioverativ Therapeutics Inc Fator recombinante viii-fc para tratamento de hemofilia e baixa densidade mineral óssea
CN114072420B (zh) 2019-07-04 2024-06-11 康诺贝林伦瑙有限公司 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf)
JP2023500953A (ja) 2019-11-11 2023-01-11 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 第ｖｉｉｉ因子に対する寛容を誘導するためのポリペプチド
US20230023826A1 (en) 2019-12-12 2023-01-26 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
JP2021156833A (ja) * 2020-03-30 2021-10-07 シスメックス株式会社 血液凝固活性の測定方法
EP4355768A1 (fr) 2021-06-14 2024-04-24 Takeda Pharmaceutical Company Limited Thérapie génique contre l'hémophilie a faisant appel à des vecteurs viraux codant pour des variants de fviii recombinés à expression accrue
WO2023028456A1 (fr) 2021-08-23 2023-03-02 Bioverativ Therapeutics Inc. Gènes de facteur viii optimisés
WO2023056331A1 (fr) 2021-09-30 2023-04-06 Bioverativ Therapeutics Inc. Acides nucléiques codant pour des polypeptides du facteur viii à immunogénicité réduite
WO2024081309A1 (fr) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Cellules modifiées et éléments implantables pour le traitement d'une maladie

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8801674A1 (es) 1985-04-12 1988-02-16 Genetics Inst Un procedimiento para la preparacion de una proteina que presenta actividad procoagulante.
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5610278A (en) 1986-06-24 1997-03-11 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
AU670793B2 (en) * 1992-04-30 1996-08-01 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor VIII complex
ATE319817T1 (de) * 1996-04-24 2006-03-15 Univ Michigan Gegen inaktivierung resistenter faktor viii
AU1598200A (en) 1998-10-23 2000-05-15 Trustees Of The University Of Pennsylvania, The Systemic delivery of gene products via skin
NZ530131A (en) 2001-06-15 2005-12-23 Andre C Gene therapy for hemophilia A

Also Published As

Publication number Publication date
LUC00023I1 (fr) 2017-06-21
DK1587832T3 (en) 2014-02-24
EP2253645A3 (fr) 2011-02-16
CA2514646C (fr) 2013-07-23
EP1587832B1 (fr) 2013-12-11
CN1745100A (zh) 2006-03-08
BE2017C021I2 (fr) 2023-03-07
EP2253645A2 (fr) 2010-11-24
US7041635B2 (en) 2006-05-09
FR17C1024I2 (fr) 2019-07-19
EP1587832A1 (fr) 2005-10-26
WO2004067566A1 (fr) 2004-08-12
HK1150840A1 (zh) 2012-01-13
NL300878I2 (nl) 2017-11-02
AU2003274766A1 (en) 2004-08-23
CA2514646A1 (fr) 2004-08-12
EP2253645B1 (fr) 2016-03-23
US20040147436A1 (en) 2004-07-29
ES2446041T3 (es) 2014-03-06
FR17C1024I1 (fr) 2017-09-08
CN100404552C (zh) 2008-07-23
AU2003274766B8 (en) 2009-08-27
KR20050044776A (ko) 2005-05-12
AU2003274766B2 (en) 2009-02-12
KR100642293B1 (ko) 2006-11-03
DK2253645T3 (en) 2016-06-27

Similar Documents

Publication Publication Date Title
FR17C1024I1 (fr)
BE2014C055I2 (fr)
BE2014C027I2 (fr)
BE2013C035I2 (fr)
BE2013C034I2 (fr)
BE2011C030I2 (fr)
JP2003286857A5 (fr)
JP2004108366A5 (fr)
JP2003298927A5 (fr)
BE2015C005I2 (fr)
JP2004072717A5 (fr)
BE2012C053I2 (fr)
JP2003314203A5 (fr)
JP2004154561A5 (fr)
JP2004164663A5 (fr)
JP2004004018A5 (fr)
JP2004055525A5 (fr)
JP2003305183A5 (fr)
JP2004175783A5 (fr)
AU2002311957A1 (fr)
AU2002329412A1 (fr)
AU2001256599A1 (fr)
AU2003210772A1 (fr)
AU2002355123A1 (fr)
IL159467A0 (fr)